MD Anderson and Hummingbird Bioscience announce strategic research collaboration to advance innovative immunotherapies
Multi-year collaboration will investigate and evaluate Hummingbird’s HMBD-002 VISTA antagonist antibody
MD Anderson News Release July 12, 2021
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience today announced the launch of a multi-year strategic research collaboration to investigate and evaluate HMBD-002, Hummingbird’s VISTA antagonist antibody.
Under the agreement, MD Anderson and Hummingbird will collaborate on the design and execution of clinical and translational research studies to better understand how HMBD-002 modulates the anti-tumor immune response, both as a monotherapy and in combination with other checkpoint inhibitors. Working with MD Anderson’s immunotherapy platform and its experts in comprehensive immunoprofiling, the teams will seek to identify biomarkers that may be used to predict clinical outcomes and adverse events.
“We are excited to be collaborating with MD Anderson to advance the clinical research of our novel immunotherapies,” said Jerome Boyd-Kirkup, Ph.D., co-founder and CSO of Hummingbird Bioscience. “These studies will strengthen our understanding of VISTA and other emerging immuno-oncology targets and help us ensure that novel treatment strategies for challenging cancers get to patients as quickly as possible.”
VISTA, an immune checkpoint protein, is an emerging immunotherapy target for cancer that suppresses the anti-tumor immune response. Studies indicate increased levels of VISTA are associated with the emergence of resistance to current cancer immunotherapies. HMBD-002 is designed to inhibit VISTA, removing the suppression of the immune system and allowing it to mount an anti-tumor response.
“Targeting VISTA is an exciting area of immunotherapy research with the potential to have an impact on a variety of cancer types,” said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology and Immunology at MD Anderson. “This collaboration aligns our expertise in studying the anti-tumor immune response with Hummingbird’s novel therapeutic pipeline. We look forward to working with Hummingbird to advance immunotherapies that we hope will improve care for our patients.”
Sharma and James Allison, Ph.D., regental chair of Immunology, are co-leaders of MD Anderson’s immunotherapy platform and will oversee the collaboration. Jordi Rodon, M.D., Ph.D., associate professor of Investigational Cancer Therapeutics and Genomic Medicine, will lead the clinical study of HMBD-002 at MD Anderson.
Drs. Sharma and Allison receive compensation as consultants to Hummingbird Bioscience, and Dr. Sharma holds equity in the company. These financial relationships have been disclosed to MD Anderson in accordance with its COI Policy.